NCT05739409已完成不适用
An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Monocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2023年2月16日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- Evaluate safety and tolerability
研究概览
简要总结
This is a single-center,single-arm,open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Monocytic Leukemia subjects.
详细描述
This study will recruit LILRB4-positive monocytic leukemia subjects who will receive cyclophosphamide and fludarabine on days -5 to -3 prior to cell infusion, followed by LILRB4 STAR-T cells. The primary objective of the study was to evaluate the safety and tolerability of LILRB4 STAR-T cells in subjects with monocytic leukemia. The secondary objective was to evaluate the therapeutic efficacy, pharmacodynamics and pharmacokinetics of LILRB4 STAR-T cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Aged 18-70 years, gender is not limited
- •Acute myelogenous leukemia or chronic monocytic leukemia:
- •Subjects diagnosed with acute myelogenous leukemia according to WHO 2016 criteria and according to the "Chinese Guidelines for the Diagnosis and Treatment of Relapsed and Refractory Acute Myeloid Leukemia (2021 Edition)" should meet any of the following relapsed and refractory (R/R) acute myelogenous leukemia patients:
- •Patients who have failed two cycles of standard chemotherapy;
- •No remission was achieved after 1 cycle of the standard regimen and could not continue with the standard regimen due to age, comorbidities, physical status, and / or adverse risk factors;
- •Relapse within 12 months after consolidation and intensification therapy after complete remission (CR);
- •Relapse after 12 months but failed to respond to conventional treatment;
- •two or more recurrences;
- •persistent extramedullary leukemia;
- •For age> 60 years: standard regimen chemotherapy due to age, comorbidities, physical status, and / or adverse risk factors, and treated with 4 cycles of demethylating drugs (such as decitabine and / or azacitidine) or 2 cycles of low-dose chemotherapy ± demethylating drugs。 Note: Definition of relapse: reoccurrence of leukemic cells in peripheral blood after CR or in bone marrow> 5% (except for other causes such as marrow regeneration after consolidation chemotherapy) or extramedullary infiltration of leukemic cells.
- •Chronic granule-monocytic leukemia (CMML) type 2 was diagnosed according to the World Health Organization (WHO) 2016 Hematopoietic and Lymphoid Tissue tumors and the Chinese Guidelines for the Diagnosis and Treatment of Chronic Grain-Monocytic Leukemia (2021 edition), and did not achieve remission after at least one treatment or relapsed after remission。
- •Eastern Cooperative Oncology Group physical status level is 0 to 2;
- •Bone marrow sample must be LILRB4 positive；
- •Major organs must meet the following criteria:
- •Liver function: Total bilirubin≤1.5 times the upper limit of normal,glutamic-pyruvic transaminase and glutamic oxalacetic transaminase≤3 times the upper limit of normal,
- •Renal function:Creatinine≤1.5 times the upper limit of normal (ULN) or creatinine clearance rate ≥60ml/min,
- •Cardiac function:LVEF≥50%，
- •Lung function:Defined as ≤grade 1 dyspnea and blood oxygen saturation >92%;
- •Female subjects of reproductive age or male subjects whose partners are women of reproductive age agree to use an effective method of contraception throughout the trial and for 12 months after cell infusion;
- •The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.
排除标准
- •Patients who have used chimeric antigen receptor T-cell immunotherapy therapy or any other gene transduction product within 3 months of signing the informed consent, except without detectable chimeric antigen receptor T-cell ratio or chimeric antigen receptor T-cell ratio below the lower test limit; or patients who have participated in other interventional clinical studies within 4 weeks prior to signing the informed consent；
- •Any of the following cardiovascular and cerebrovascular diseases occurred within 6 months before screening:
- •congestive heart failure(NYHA stage III),myocardial infarction,unstable angina pectoris,congenital long QT syndrome,Anterior left block,coronary angioplasty,stent implantation,Coronary/peripheral artery bypass grafting,cerebrovascular accident,Transient ischemic attack or pulmonary embolism,Asymptomatic right bundle branch block was allowed;
- •Serious arrhythmias requiring treatment (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes, etc.);
- •uncontrolled hypertension (systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 100 mmHg), a history of hypertensive crisis or hypertensive encephalopathy;
- •Subjects with positive hepatitis B surface antigen (HBsAg) or positive hepatitis B core antibody (HBcAb) and hepatitis B virus DNA copy number above the detection limit; subjects with positive hepatitis C virus (HCV) antibody and positive HCV RNA copy number above the detection limit; positive pallidum antibody test；
- •Patients with known systemic lupus erythematosus, combined active or uncontrolled autoimmune diseases (such as Crohns disease, rheumatoid arthritis, autoimmune hemolytic anemia, etc.), primary or secondary immune deficiency (such as HIV infection or severe infectious diseases, etc.)；
- •Previous or concurrent other incurable malignancies with unstable control,Affect the long-term survival of subjects, except for cured cervical carcinoma in situ, non-invasive basal cell or squamous cell skin cancer or other local prostate cancer after radical treatment, ductal carcinoma in situ after radical resection and at least 5 Years without recurrence of malignant tumor;
- •Patients with current disease or a previous history of central nervous system disease, such as seizures, stroke, severe brain injury, aphasia, paralysis, dementia, Parkinson's disease, mental illness, etc；
- •Patients living with an active central nervous system leukemia (CNSL)；
- •Patients who had prior solid organ transplantation or allogeneic hematopoietic stem cell transplantation (allo-HSCT) 6 months before screening；
- •Subjects with aGVHD and cGVHD at screening；
- •Subjects who have had any of the following drugs or treatments within the specified time period prior to apheresis:
- •Administered any immunosuppressant within 2 weeks prior to apheresis;
- •Received any chemotherapy within 2 weeks or 3 half-lives, whichever is shorter, prior to apheresis;
- •Received any macromolecule or small molecule targeted therapy such as monoclonal antibody, antibody-drug conjugate (ADC), double antibody, etc. within 4 weeks before apheresis or within 3 half-lives (whichever is shorter);
- •Those with mental illness or history of drug abuse;
- •Pregnant or breastfeeding subjects;
- •The investigator believes that there are other factors that are not suitable for inclusion or that affect subjects participating in or completing the study.
研究组 & 干预措施
LILRB4 STAR-T cells injection
Experimental
The study was divided into two phases: dose climbing and dose extension. Dose climbing stage: adopt the 3 + 3 dose climbing design principle, and the dose group is set as follows, in which, dose group-A is the backup dose reduction dose group, and dose group A is the starting dose:
Dose Group-A: 3×105STAR+T cells / kg； Dose group A: 1×106STAR+T cells / kg； Dose group B: 3×106STAR+T cells / kg； Dose group C: 6×106STAR+T cells / kg； Dose group D: 1×107STAR+T cells / kg。
干预措施: LILRB4 STAR-T cells injection (Biological)
结局指标
主要结局
Evaluate safety and tolerability
时间窗: 12 months
Subjects are observed for dose-limiting toxicity(DLT) after LILRB4 STAR-T cells infusion, with the recording of adverse events(AE) and serious adverse events(SAE), with a focus on cytokine release syndrome(CRS) and immune cell-associated neurotoxicity(ICANS).All of the AE ratings were assessed according to the CTCAE.
次要结局
- Antitumor efficacy(12 months)
研究者
wang, jianxiang
Professor
Institute of Hematology & Blood Diseases Hospital, China
研究点 (2)
Loading locations...
相似试验
已完成
1 期
LILRB4 STAR-T Cells in the Treatment of R/R AML/CMMLNCT05548088Peking University People's Hospital11
招募中
1 期
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05913804Institute of Hematology & Blood Diseases Hospital, China12
已完成
1 期
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid LeukemiaNCT05518357Hebei Yanda Ludaopei Hospital2
尚未招募
1 期
MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid TumorsNCT05344976Peking University12
招募中
1 期
Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid TumorsCDH17-positive Advanced Malignant Solid TumorsNCT06501183Shanghai Pudong Hospital17